Epstein‐Barr Virus‐related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti‐CD30. Issue 6 (8th April 2020)

• Record Type: Journal Article
• Authors: Montes, Lydia; Tredez, Estelle; Yzet, Clara; Delette, Caroline; Chatelain, Denis; Lebon, Delphine; Fumery, Mathurin; Marolleau, Jean‐Pierre
• Is Part Of: Clinical case reports. Volume 8:Issue 6(2020)
• Page Start: 958
• Page End: 961
• Publication Date: 2020-04-08
• Subjects: brentuximab vedotin -- CD30 -- epstein‐barr virus -- immunosuppression -- lymphoma; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.2721
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Epstein‐Barr virus‐related mucocutaneous ulcer lymphoma is a rare entity promoted by immunosuppression. It is less described in inflammatory bowel diseases, and mostly these are refractory diseases. CD30 acts to Epstein‐Barr virus (EBV) local proliferation and thus could be an interesting target. Brentuximab vedotin could become a new helpful tool. Abstract : Epstein‐Barr virus‐related mucocutaneous ulcer lymphoma is a rare entity promoted by immunosuppression. It is less described in inflammatory bowel diseases, and mostly these are refractory diseases. CD30 acts to Epstein‐Barr virus (EBV) local proliferation and thus could be an interesting target. Brentuximab vedotin could become a new helpful tool.